Skip to main content
Fig. 2 | Respiratory Research

Fig. 2

From: In vivo miR-138-5p inhibition alleviates monocrotaline-induced pulmonary hypertension and normalizes pulmonary KCNK3 and SLC45A3 expression

Fig. 2

In vivo inhibition of miR-138-5p stops the alteration of pulmonary arterial flow as shown by echocardiography. In rats with MCT-PH, a quantification of the pulmonary acceleration time (PAAT) 3 weeks after MCT injection (n = 6 per group). b Evolution of the PAAT in MCT-exposed rats before (2 weeks) and after anti-miR (anti-miR-Control and anti-miR-138-5p) treatment (3 weeks). c Quantification of the pulmonary artery velocity time integral (VTI-PA) 3 weeks after MCT injection. d Evolution of the VTI-PA in MCT-exposed rats before (2 weeks) and after anti-miR treatment (3 weeks). *P < 0.05, **P < 0.01

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us